Back to News
Market Impact: 0.35
Enlivex Therapeutics Ltd. Receives Nasdaq Delisting Notice and Announces 1-for-16 Reverse Split
Source: Nasdaq
Regulation & LegislationCompany Fundamentals
Enlivex Therapeutics said it received a Nasdaq delisting notification on October 26, 2026, concerning the closing bid price of its ordinary shares over a 30-consecutive-business-day period. The provided article text is truncated, so it does not specify the applicable price threshold, the company’s compliance period, or any further steps.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.35
Ticker Sentiment
ENLV-0.75
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic IPO Seeks Investors, With Risks of Catastrophe, Rogue AI
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios